|
|
Article: 3M Pharmaceuticals Announces Long-term Clinical Benefits of Aldara Cream for Actinic Keratosis.
- Article from:
- Business Wire
- Article date:
- June 20, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ST. PAUL, Minn. -- - Majority of Patients Had No Recurrence or New AK Lesions One and One-half Years Post-treatment -
According to a recent study published in the June issue of Dermatologic Surgery, prescription Aldara (imiquimod) cream, 5% delivers long-term clinical benefits in the treatment of actinic keratosis (AK), a precancerous skin condition caused by chronic sun exposure. Led by an investigator at the University of Minnesota, the study showed 75 percent of patients treated with Aldara Cream three times per week, and nearly 60 percent treated two times per week, continued to demonstrate complete clearance of AK after a follow-up period of 12 to 18 months. ...